Agios Pharmaceuticals (NASDAQ: AGIO) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(1.67) by 1.2 percent. This is a 12.44 percent increase over losses of $(1.93) per share from the same period last year. The company reported quarterly sales of $44.745 million which beat the analyst consensus estimate of $25.521 million by 75.32 percent. This is a 259.25 percent increase over sales of $12.455 million the same period last year.